QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

$44.87
-0.59 (-1.30%)
(As of 04:25 PM ET)
Today's Range
$44.44
$45.47
50-Day Range
$43.53
$53.55
52-Week Range
$32.69
$54.44
Volume
1.22 million shs
Average Volume
1.30 million shs
Market Capitalization
$6.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.23

Ionis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.54 Rating Score
Upside/​Downside
18.5% Upside
$53.23 Price Target
Short Interest
Bearish
6.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.63mentions of Ionis Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$12.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.92) to ($3.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.73 out of 5 stars

Medical Sector

263rd out of 948 stocks

Pharmaceutical Preparations Industry

119th out of 440 stocks


IONS stock logo

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

IONS Stock Price History

IONS Stock News Headlines

Ionis to present at upcoming investor conferences
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $63.00
Q4 2023 Ionis Pharmaceuticals Inc Earnings Call
IONS Mar 2024 40.000 put
Ionis' Olezarsen Receives FDA Orphan Drug Designation
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/04/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
927
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.23
High Stock Price Target
$70.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+17.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
13 Analysts

Profitability

Net Income
$-366,290,000.00
Pretax Margin
-42.40%

Debt

Sales & Book Value

Annual Sales
$788 million
Book Value
$2.70 per share

Miscellaneous

Free Float
141,890,000
Market Cap
$6.63 billion
Optionable
Optionable
Beta
0.40
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















IONS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IONS shares.
View IONS analyst ratings
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price target for 2024?

13 Wall Street research analysts have issued 12 month price objectives for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $28.00 to $70.00. On average, they expect the company's share price to reach $53.23 in the next year. This suggests a possible upside of 18.5% from the stock's current price.
View analysts price targets for IONS
or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2024?

Ionis Pharmaceuticals' stock was trading at $50.59 at the start of the year. Since then, IONS shares have decreased by 11.2% and is now trading at $44.93.
View the best growth stocks for 2024 here
.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a increase in short interest in February. As of February 15th, there was short interest totaling 9,060,000 shares, an increase of 7.2% from the January 31st total of 8,450,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is presently 7.4 days. Currently, 6.8% of the shares of the company are sold short.
View Ionis Pharmaceuticals' Short Interest
.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IONS earnings forecast
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.72. The company earned $325 million during the quarter, compared to the consensus estimate of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative trailing twelve-month return on equity of 90.29%. The company's revenue was up 113.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.37) earnings per share.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.90%), Bellevue Group AG (6.07%), Clearbridge Investments LLC (3.28%), Price T Rowe Associates Inc. MD (2.97%), Tweedy Browne Co LLC (2.41%) and BVF Inc. IL (1.69%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen.
View institutional ownership trends
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IONS) was last updated on 3/4/2024 by MarketBeat.com Staff